Analyst consensus rating
20/20 Biolabs Analyst Rating: none
AIDX is rated none by 1 analysts with a $5.00 target. As of 2026-08-21.
Direct answer
20/20 Biolabs's consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.00.
Forecast evidence checked August 21, 2026.
Get free 20/20 Biolabs email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.51
- Average price target
- $5.00
- High price target
- $5.00
- Low price target
- $5.00
- Low target gap
- +872.6%
- Target upside
- +872.6%
- High target gap
- +872.6%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- August 21, 2026
- Valid through
- August 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for 20/20 Biolabs?
20/20 Biolabs has a verified none consensus. The same dataset has an average price target of $5.00.
How far are 20/20 Biolabs's low and high targets from the recorded price?
The low target implies +872.6%, while the high target implies +872.6%.
How many analysts are included in 20/20 Biolabs's consensus?
The verified consensus includes 1 analysts.
How is 20/20 Biolabs's target upside or downside calculated?
The average target of $5.00 is divided by the recorded price of $0.51, then one is subtracted to produce +872.6%. This does not guarantee a future return.
When was 20/20 Biolabs's analyst forecast verified?
The data was verified on 2026-08-21. The dataset is valid through 2026-08-28.